The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin
Open accessAbstract
Galectin-3 (Gal-3) is secreted by activated macrophages. In hypertension, Gal-3 is a marker for hypertrophic hearts prone to develop heart failure. Gal-3 infused in pericardial sac leads to cardiac inflammation, remodeling, and dysfunction. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a naturally occurring tetrapeptide, prevents and reverses inflammation and collagen deposition in the heart in hypertension and heart failure postmyocardial infarction. In the present study, we hypothesize that Ac-SDKP prevents Gal-3-induced cardiac inflammation, remodeling, and dysfunction, and these effects are mediated by the transforming growth factor (TGF)-β/Smad3 signaling pathway. Adult male rats were divided into four groups and received the following intrapericardial infusion for 4 wk: 1) vehicle (saline, n = 8); 2) Ac-SDKP (800 μg·kg−1·day−1, n = 8); 3) Gal-3 (12 μg/day, n = 7); and 4) Ac-SDKP + Gal-3 ( n = 7). Left ventricular ejection fraction, cardiac output, and transmitral velocity were measured by echocardiography; inflammatory cell infiltration, cardiomyocyte hypertrophy, and collagen deposition in the heart by histological and immunohistochemical staining; and TGF-β expression and Smad3 phosphorylation by Western blot. We found that, in the left ventricle, Gal-3 1) enhanced macrophage and mast cell infiltration, increased cardiac interstitial and perivascular fibrosis, and causes cardiac hypertrophy; 2) increased TGF-β expression and Smad3 phosphorylation; and 3) decreased negative change in pressure over time response to isoproterenol challenge, ratio of early left ventricular filling phase to atrial contraction phase, and left ventricular ejection fraction. Ac-SDKP partially or completely prevented these effects. We conclude that Ac-SDKP prevents Gal-3-induced cardiac inflammation, fibrosis, hypertrophy, and dysfunction, possibly via inhibition of the TGF-β/Smad3 signaling pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715 · cited 1×
“Hochberg and Benjamini’s (15) method for multiple comparisons was used to adjust the -level of significance.”
MethodThe inflammatory response in myocardial infarction
Frangogiannis, N. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00434-5 · Cited by 2,011
Inflammatory Mediators and the Failing Heart: Past, Present, and the Foreseeable Future
Mann, D. L. (2002) · Circulation Research · doi:10.1161/01.res.0000043825.01705.1b · Cited by 988
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958
Sharma, U. C., Pokharel, S., van Brakel, T. J., van Berlo, J. H., Cleutjens, J. P. M., Schroen, B., André, S., Crijns, H. J. G. M., Gabius, H. J., Maessen, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000147181.65298.4d · Cited by 947
Self-citationThe role of TGF-β signaling in myocardial infarction and cardiac remodeling
BUJAK, M., & FRANGOGIANNIS, N. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.002 · Cited by 927
van Kimmenade, R. R., Januzzi, J. L., Ellinor, P. T., Sharma, U. C., Bakker, J. A., Low, A. F., Martinez, A., Crijns, H. J., MacRae, C. A., Menheere, P. P., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.061 · Cited by 567
Self-citationvan Amerongen, M. J., Harmsen, M. C., van Rooijen, N., Petersen, A. H., & van Luyn, M. J. A. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060547 · Cited by 544
Regulation of Alternative Macrophage Activation by Galectin-3
MacKinnon, A. C., Farnworth, S. L., Hodkinson, P. S., Henderson, N. C., Atkinson, K. M., Leffler, H., Nilsson, U. J., Haslett, C., Forbes, S. J., & Sethi, T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2650 · Cited by 543
Ahmad, N., Gabius, H.-J., André, S., Kaltner, H., Sabesan, S., Roy, R., Liu, B., Macaluso, F., & Brewer, C. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312834200 · Cited by 517
Self-citationRat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1.
Damoiseaux, J. G. M. C., Döpp, E. A., Calame, W., Chao, D., MacPherson, G. G., & Dijkstra, C. D. (1994) · PubMed · Cited by 513
SIRIUS RED F3BA AS A STAIN FOR CONNECTIVE TISSUE.
Sweat, F., Puchtler, H., & Rosenthal, S. I. (1964) · PubMed · Cited by 424
Azizi, M., Rousseau, A., Ezan, E., Guyene, T. T., Michelet, S., Grognet, J. M., Lenfant, M., Corvol, P., & Ménard, J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118484 · Cited by 339
Papaspyridonos, M., McNeill, E., de Bono, J. P., Smith, A., Burnand, K. G., Channon, K. M., & Greaves, D. R. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.159160 · Cited by 236
Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling
Zhan, Y. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24403 · Cited by 209
Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action
Peng, H., Carretero, O. A., Vuljaj, N., Liao, T.-D., Motivala, A., Peterson, E. L., & Rhaleb, N.-E. (2005) · Circulation · doi:10.1161/circulationaha.104.528695 · Cited by 160
Self-citationMilting, H., Ellinghaus, P., Seewald, M., Cakar, H., Bohms, B., Kassner, A., Körfer, R., Klein, M., Krahn, T., Kruska, L., et al. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.02.018 · Cited by 158
A role for cardiac mast cells in the pathogenesis of hypertensive heart disease
Shiota, N., Rys??, J., Kovanen, P. T., Ruskoaho, H. J., Kokkonen, J. O., & Lindstedt, K. A. (2003) · Journal of Hypertension · doi:10.1097/00004872-200310000-00022 · Cited by 141
Gabius, H. (2006) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v26.i1.30 · Cited by 139
Self-citationGlycosaminoglycans in rat mucosal mast cells
Enerbäck, L., Kolset, S. O., Kusche, M., Hjerpe, A., & Lindahl, U. (1985) · Biochemical Journal · doi:10.1042/bj2270661 · Cited by 136
Ac-SDKP Reverses Inflammation and Fibrosis in Rats With Heart Failure After Myocardial Infarction
Yang, F., Yang, X.-P., Liu, Y.-H., Xu, J., Cingolani, O. H., Rhaleb, N., & Carretero, O. A. (2003) · Hypertension · doi:10.1161/01.hyp.0000107777.91185.89 · Cited by 131
Self-citationVillalobo, A., Nogales, A., & Gabius, H. (2006) · Trends in Glycoscience and Glycotechnology · doi:10.4052/tigg.18.1 · Cited by 124
Self-citationSharma, U. C., Rhaleb, N., Pokharel, S., Harding, P., Rasoul, S., Peng, H., & Carretero, O. A. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00305.2007 · Cited by 122
Self-citationAndré, S., Unverzagt, C., Kojima, S., Frank, M., Seifert, J., Fink, C., Kayser, K., von der Lieth, C., & Gabius, H. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03910.x · Cited by 118
Self-citationIntegrins, Vascular Remodeling, and Hypertension
Heerkens, E. H. J., Izzard, A. S., & Heagerty, A. M. (2006) · Hypertension · doi:10.1161/01.hyp.0000252753.63224.3b · Cited by 112
Peng, H., Carretero, O. A., Raij, L. R., Yang, F., Kapke, A., & Rhaleb, N. (2001) · Hypertension · doi:10.1161/01.hyp.37.2.794 · Cited by 104
Self-citationRhaleb, N., Peng, H., Harding, P., et al. (2001) · Hypertension · doi:10.1161/01.hyp.37.3.827 · Cited by 97
Self-citationAntifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension
Rasoul, S., Carretero, O. A., Peng, H., Cavasin, M. A., Zhuo, J. L., Sánchez-Mendoza, A., Brigstock, D. R., & Rhaleb, N. (2004) · Journal of Hypertension · doi:10.1097/00004872-200403000-00023 · Cited by 96
Self-citationDoppler echocardiographic estimation of left ventricular end-diastolic pressure after MI in rats
Prunier, F., Gaertner, R., Louedec, L., Michel, J., Mercadier, J.-J., & Escoubet, B. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01050.2001 · Cited by 91
Liu, J., Lawrence, F., Filipović, M. K., Bignon, J. S., Papadimitriou, Ε., Lallemand, J., Katsoris, P., Potìer, P., Fromes, Y., & Wdzieczak‐Bakala, J. (2003) · Blood · doi:10.1182/blood-2002-07-2315 · Cited by 84
Decreased Endogenous Levels of Ac-SDKP Promote Organ Fibrosis
Cavasin, M. A., Liao, T., Yang, X.-P., Yang, J. J., & Carretero, O. A. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.084103 · Cited by 81
Self-citationN-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo
Wang, D., Carretero, O. A., Yang, X., Rhaleb, N., Liu, Y., Liao, T., & Yang, X.-P. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00592.2004 · Cited by 74
Self-citationPokharel, S., van Geel, P. P., Sharma, U. C., Cleutjens, J. P. M., Bohnemeier, H., Tian, X., Schunkert, H., Crijns, H. J. G. M., Paul, M., & Pinto, Y. M. (2004) · Circulation · doi:10.1161/01.cir.0000147180.87553.79 · Cited by 72
Self-citationAc-SDKP Reverses Cardiac Fibrosis in Rats With Renovascular Hypertension
Peng, H., Carretero, O. A., Brigstock, D. R., Oja-Tebbe, N., & Rhaleb, N. (2003) · Hypertension · doi:10.1161/01.hyp.0000100423.24330.96 · Cited by 70
Self-citationRhaleb, N., Peng, H., Yang, X.-P., et al. (2001) · Circulation · doi:10.1161/01.cir.103.25.3136 · Cited by 68
Self-citationBelvisi, L., Bernardi, A., Colombo, M., Manzoni, L., Potenza, D., Scolastico, C., Giannini, G., Marcellini, M., Riccioni, T., Castorina, M., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.08.048 · Cited by 64
N -Acetyl-Ser-Asp-Lys-Pro Inhibits Phosphorylation of Smad2 in Cardiac Fibroblasts
Pokharel, S., Rasoul, S., Roks, A. J. M., van Leeuwen, R. E. W., van Luyn, M. J. A., Deelman, L. E., Smits, J. F. M., Carretero, O. A., van Gilst, W. H., & Pinto, Y. M. (2002) · Hypertension · doi:10.1161/01.hyp.0000025880.56816.fa · Cited by 56
Self-citationCingolani, O. H., Yang, X.-P., Liu, Y.-H., Villanueva, M., Rhaleb, N., & Carretero, O. A. (2004) · Hypertension · doi:10.1161/01.hyp.0000125013.22494.c5 · Cited by 45
Self-citationResident Cardiac Mast Cells: Are They the Major Culprit in the Pathogenesis of Cardiac Hypertrophy?
Balakumar, P., Singh, A. P., Ganti, S. S., et al. (2007) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00147.x · Cited by 44
Cited by
Murphy, S. P., Kakkar, R., McCarthy, C. P., & Januzzi, J. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.014 · Cited by 738
Chow, S. L., Maisel, A. S., Anand, I., Bozkurt, B., de Boer, R. A., Felker, G. M., Fonarow, G. C., Greenberg, B., Januzzi, J. L., Kiernan, M. S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000490 · Cited by 601
Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community
Ho, J. E., Liu, C., Lyass, A., Courchesne, P., Pencina, M. J., Vasan, R. S., Larson, M. G., & Levy, D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.053 · Cited by 589
Galectin-3: A Novel Mediator of Heart Failure Development and Progression
de Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H., & van Veldhuisen, D. J. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp097 · Cited by 524
Lok, D. J. A., Van Der Meer, P., de la Porte, P. W. B.-A., Lipsic, E., Van Wijngaarden, J., Hillege, H. L., & van Veldhuisen, D. J. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0125-y · Cited by 465
Metadata
- Authors
- Liu, Y.-H., D'Ambrosio, M., Liao, T.-D., Peng, H., Rhaleb, N.-E., Sharma, U., André, S., Gabius, H.-J., & Carretero, O. A.
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2009-02
- Volume
- 296
- Issue
- 2
- Pages
- H404-H412
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W2014189665
- Cited by
- 269
- References
- 39
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.